Heart Failure Pharmacological Management: Gaps and Current Perspectives

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Heart failure (HF) management presents significant challenges for cardiologists.
• Current guidelines recommend four drug classes: ACEi/ARNI, BB, MRAs, and SGLT2i to reduce HF-related mortality and hospitalizations.

Purpose of the Study:

• To review current gaps and future perspectives in the pharmacological management of HF patients.
• To address uncertainties in therapeutic strategies for both acute and chronic heart failure settings.

Main Methods:

• Literature review of current guidelines and recent research on HF pharmacotherapy.
• Analysis of therapeutic algorithms based on left ventricular ejection fraction and clinical presentation.
• Discussion of differing approaches to initiating and dosing foundational HF medications.

Main Results:

• Guidelines lack specific recommendations on the order and dosage of initiating the four pillar HF drugs.
• Current therapeutic algorithms may not fully capture precise hemodynamic status or pathophysiological mechanisms, especially in acute HF.
• Emerging strategies include initiating SGLT2i and BB first, ACEi/ARNI first, or all four drugs concurrently at low doses.

Conclusions:

• Significant ambiguities persist regarding the optimal sequencing and titration of foundational pharmacotherapies in heart failure.
• Further research is needed to define precise, evidence-based strategies for initiating and managing ACEi/ARNI, BB, MRAs, and SGLT2i in diverse HF patient populations.
• Clarifying these aspects is crucial for optimizing patient outcomes in both acute and chronic heart failure management.